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The prevalence of chronic heart failure in European countries is
about 1–2% with a significant increase in elderly population.
Based on the results of EUROHEART survey the prevalence inEastern Europe is 1.3%. Improved treatment of acute stages
(especially acute myocardial infarction) leads to the higher
number of patients with chronic heart failure. Chronic heart
failure has bad prognosis, diagnostics and treatment are
demanding not only in medical but also economical way.
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Completely and fully accepted definition of heart failure is not
available. Most used definition highlight one or several
features of this complex syndrome such as haemodynamics
and evidence about neurohumoral activation. The term of
chronic heart failure is thereby a description for many
symptoms and signs which are caused by failed heart
function. Chronic heart failure is a syndrome of heart
impairment which leads to the decreasing minute cardiac
output and disability to cover metabolic demands of tissues
even the filling of the ventricles is not affected. Symptoms of
heart failure can be present even without decrease of cardiac
output during an inappropriate increase of end diastolic
ventricular pressure (Tables 1 and 2).Table 1 – Classes of recommendation.
Classes of recommendations
I Evidence and/or general agreement that a given treatment
or procedure is beneficial, useful, effective
II Conflicting evidence and/or a divergence of opinion about
the usefulness/efficacy of given treatment or procedure
IIa Weight of evidence/opinion is in favour of usefulness/
efficacy
IIb Usefulness/efficacy is less well established by evidence/
opinion
III Evidence and/or general agreement that a given treatment
or procedure is not useful/effective and in some cases may
be harmful
Notice: class of recommendation III is not mentioned in these
guidelines.
Table 3 – Diagnostic criteria of heart failure.
1. Symptoms typical of heart failure (breathlessness at rest or on
exercise, fatigue, tiredness)
2. Signs typical of heart failure (tachycardia, tachypnoea,
pulmonary rales, pleural effusion, raised jugular venous pressure,
gallop rhythm, peripheral oedema, hepatomegaly, cardiomegaly,
third heart sound, heart murmurs)
3. Proven heart dysfunction at the rest (objectively documented
systolic or diastolic dysfunction during echocardiography or other
imaging test, increased natriuretic peptides)
4. Response to treatment (in a case of unsure diagnosis)
Table 2 – Levels of evidence.
Levels of evidence
A Data derived from 42 large randomized clinical trials or
meta-analysis
B Data derived from 1 large randomized clinical trial and
multiple smaller or non-randomized trials
C Consensus of opinion of experts based on small studies or
retrospective trials and registriesSymptoms, signs and objectively proven heart dysfunction
must be present to make a diagnosis of chronic heart failure
(Table 3).
Heart dysfunction may be divided into Systolic, when contractility of heart is affected which
leads into decreased ejection fraction and lower cardiac
output. Diastolic, when the fulfilment of heart ventricles is
affected, most often because of the loss of compliance
and worst expandability of heart ventricle. Isolated affec-
tion of diastolic function is called heart failure with
preserved ejection fraction (HFPEF).
Generally, heart failure can be classified into Acute—first presentation, acute or slow onset.
 Transient—recurrent or episodic.
 Chronic—persistent, stable, worsening, or decompensated.
The term asymptomatic ventricular dysfunction is de-
scribed as a presence of decreased systolic/diastolic ventri-
cular function and the patient is asymptomatic without any
treatment, meanwhile heart failure stage NYHA I means
when the patient is treated and asymptomatic.3. Aetiology, epidemiology and prognosis
3.1. Aetiology
Many cardiovascular diseases lead into ventricular myocardial
dysfunction, which is the proper cause of heart failure. This
dysfunction may be systolic or/and diastolic. Coronary heart
disease, especially the status after the myocardial infarction is
by far the most common cause of myocardial disease, being the
initiating cause in about 70% of patients with HF. Valve disease
accounts for 10% and cardiomyopathies, usually dilated cardi-
omyopathy, for another 10% [1,2]. Other causes are less
common. Aetiology of heart failure with preserved ejection
fraction (HFPEF) is different. Most common cause is hyperten-
sion, especially in elderly population, when the diastolic
dysfuntion is worsened by myocardial fibrosis. Diabetes melli-
tus play also an important role in aetiology of HFPEF.
Heart failure is a syndrome and should never be presented
as a final diagnosis. Aetiological diagnosis should always be
specified because it may have a crucial impact on choice of
optimal treatment.
3.2. Epidemiology
In developed countries including the Czech Republic cardio-
vascular and coronary events mortality is decreasing for the
last 20–30 years. Contrary to this positive fact the overall
prevalence of HF is increasing because of the ageing of the
population, the success in treatment of acute coronary
events, and improved pharmacological treatment and whole
treatment management. The prevalence of HF is about 2%
and rises sharply at 75 years of age, so the prevalence in 70- to
Table 4 – Functional classification of heart failure
according to New York Heart Association (NYHA).
Modified in 1994.
NYHA ACC/AHA
2005
Definition
Class I Stage B No limitation of physical activity.
Ordinary physical activity does not
cause undue fatigue, palpitation, or
dyspnoea. Patients can handle
ordinary physical activity including
walking or running 8 km/h
Class II Stage C Slight limitation of physical activity.
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asymptomatic ventricular dysfunction is similar, about 2% [3].
That means that more than 200,000 patients suffer from heart
failure and the similar amount of patients has asymptomatic
ventricular dysfunction in the Czech Republic.
3.3. Prognosis
The outlook is, in general, gloomy, although it has improving
tendencies. Overall 50% of patients are dead at 4 years and
more than 50% of patients with severe heart failure (NYHA IV)
are dead at 1 year [4,5]. Forty percent of patients admitted to
hospital with HF are dead or readmitted within 1 year.
Comfortable at rest, but ordinary
physical activity results in fatigue,
palpitation, or dyspnoea. Patients can
handle less than ordinary activity but
ordinary activity results in fatigue or
dyspnoea
Class III Stage C Marked limitation of physical
activity. Comfortable at rest, but less
than ordinary activity results in
fatigue, palpitation, or dyspnoea.
Patients suffer from dyspnoea or
fatigue during basic activity such as
dressing or washing
Class IV Stage D Unable to carry on any physical
activity without discomfort. Dyspnoea
or palpitation at rest. Patients are
unable of independent life
Note: ACC/AHA 2005 stage A are high risk patients for developing
heart failure (hypertension, diabetes mellitus, renal failure, pulmon-
ary disease) without identified structural or functional abnormality.4. Pathophysiology
Low cardiac output leads to the insufficient fulfillment of
arterial bloodstream. This situation is registered by peripheral
receptors. Signals from chemo- and mechanoreceptors leads to
the activation of sympathoadrenal system, renin-angiotensin-
aldosterone system and nonosmotic releasing of vasopressin
and cytokines. These changes in neurovegetative system lead
into vasoconstriction which together with retention of sodium
is meant to provide perfusion of vitally important organs.
Besides progression of myocardial impairment chronic heart
failure leads into changes in lung, liver, kidney and peripheral
muscle tissues. Late stages of chronic heart failure are
connected with muscle atrophy, cachexia, often cardiac liver
cirrhosis, anaemia and coagulation disorders.
4.1. Symptoms and signs of heart failure
The symptoms of HF such as breathlessness, tiredness, fatigue
and peripheral oedema leads the physician into suspicion of
heart failure, but particularly in the elderly, obese and women
may be a problem their correct interpretation. Breathlessness, dyspnoea, which first occur after exertion,
lately in rest. The main cause is the increased diastolic
pressure in left ventricle, left atrium and pulmonary
capillars which leads into pulmonary venous congestion
because of systolic or diastolic left ventricle dysfunction. Cough, during exertion, mental stress or angriness (be-
ware cough in patients treated by ACE-I because of the
intolerance of ACE-I). Tiredness and fatigue—the cause is low cardiac output,
peripheral hypoperfusion with an inadequate supply of
oxygen and nutrients into muscles and other tissues. Peripheral oedema, the cause are stasis of blood in venous
bloodstream (systemic venous congestion) because of
right ventricle dysfunction and activation of renin-angio-
tensin-aldosterone system with retention of sodium and
water and decreased renal functions because of lower
cardiac output. Chest pain, because of ischaemic heart disease.
The severity of heart failure is most often classified into
four functional classes using the NYHA functional classifica-
tion (Table 4). American guidelines adjust classification intostages A–D. Stage A is defined as high risk for developing
heart failure (hypertension, aterosklerotic disease, obesity,
etc.) with any identified structural or functional abnormality
of myocardium. Stage B includes asymptomatic dysfunction
of left ventricle and class NYHA I, Stage C are asymptomatic
patients—NYHA II and III, Stage D refractory heart failure
(NYHA IV) despite maximal therapy [6].
Dominating symptoms and signs of left heart failure are
caused by pulmonary congestion (venous stasis). The symp-
toms are dyspnoea after exertion worsening with progression of
HF, paroxysmal nocturnal dyspnoea (also called asthma
cardiale) which occurs after few hours from lie down and impel
patient to sit (orthopnoea) which leads to subjective relieve.
Pulmonary oedema is the most severe manifestation of acute or
acutely decompensated chronic left heart failure [1,2].
Signs of pulmonary congestion are crackles or rales over
lungs. Severe forms of chronic heart failure leads to unilateral
or more often bilateral pleural effusion.
Objective signs of right heart failure are usually caused by
venous stasis before right heart ventricle which leads to
raised venous pressure. Typical signs includes: raised jugular
venous pressure [7], hepatojugular reflux, hepatomegaly and
peripheral oedema. Oedema first occurs as bilateral plastic
ankle swelling. At the moment of peripheral oedema mani-
festation 3–5 l of extracellular fluid is already retained.
Sensitive indicator of fluid retention is raise of patient’s
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effective diuretic therapy. Extreme form of peripheral oedema
is anasarca which is usually connected with ascites, hydro-
thorax and eventually hydropericardium [8].
Patients with heart failure usually suffers from tachycardia
as a sign of sympathoadrenal activation. III. and IV. heart
sound or their summation can be found in patients with heart
failure because of reduction of myocardial compliance. This
auscultation finding is called gallop rhythm and is mostly
heard at the heart apex. Gallop rhythm is a sign important for
prognosis and treatment of heart failure. Pulsus alternans,
alterning big and small amplitude of pulse wave, is usual sign
of severe heart failure. Lateral and inferior displacement of
the apex beat indicates enlargement of the heart, lateral
displacement with forceful impulse indicedes left ventricle
hypertrophy, palpable pulsation of precordium indicates right
ventricle hypertrophy. Accentuated II. heart sound above
pulmonary valve indicates pulmonary hypertension [9].
The symptoms and signs of HF as breathlessness, tiredness,
tachycardia, and auscultation of cracles caused by pulmonary
congestion may lead the physician to think about the possibility
of heart failure. Unfortunately these signs and symptoms have
low specificity and sensitivity which leads into undiagnosed early
stages of heart failure or into wrong diagnosis of heart failure.
False positive diagnosis is usually caused by patients obesity,
unrecognised myocardial ischaemia, chronic obstructive lung
disease or anaemia. Dyspnoea as a leading sign of left heart
failure is moderately sensitive (66%) and has a low specificity
(52%). Very useful for the diagnosis is positive response to the
treatment such as remission of dyspnoe after treatment with
diuretics [10].
Signs and symptoms of chronic heart failure are sum-
marised in Table 5.
Diagnosis of heart failure based on signs and symptoms is
highly unreliable. Objective prove of systolic and/or diastolic
heart function impairment is necessary to increase reliability of
diagnosis. Several methods are available for this purpose such as
Doppler echocardiography, nuclear medicine methods and heartTable 5 – Signs and symptoms of chronic heart failure.
Pulmonary Cardiac
Signs Cracles Tachycard
Pleural effusion III. or IV. h
Tachypnoea Cardiac d
Left ventr
Irregular p
Symptoms Dyspnoea Palpitatio
Ortopnoea Stenocard
Caught
Astma kardialecatheterization allowing evaluate systolic and diastolic heart
function.
4.2. Laboratory tests
A routine diagnostic evaluation of patients with suspected HF
includes a complete blood count, serum electrolytes, serum
creatinine, glucose, liver function tests, and urinalysis.
Increased haematocrit among patients with dyspnoea
shows more likely pulmonary cause of this symptom.
Anaemia on the contrary is often found in patients with
severe heart failure mostly because of insufficient production
of erythropoietin caused by renal impairment. Large clinical
trials shows little decrease of haematocrit caused by renin-
angiotensin-aldosterone blockers therapy. Increased values of
serum urea and creatinine most likely signify renal origin of
peripheral oedema (except the patients with terminal heart
insufficiency). Nevertheless a differential diagnosis of this
laboratory status includes also prerenal causes and catabo-
lism during heart failure. Urinalysis can reveal proteinuria
and glycosuria and thereby expose renal impairment or
diabetes mellitus which can further complicate heart failure.
Treatment with diuretics affect kalaemia, hyponatraemia is
an indicator of bad prognosis. Increased liver function tests
are caused by hypoperfusion of livers.
In patients with atrial fibrillation with fast ventricle response
thyrotoxicosis and pulmonary embolism has to be excluded.
The prove of hypothyroidism can explain one of the causes of
heart failure. Abnormalities in partial pressure of blood gases
including higher arteriovenous difference of oxygen saturation
can be found in patients with severe heart failure.
Plasma concentrations of natriuretic peptides, especially
B-type natriuretic peptide (BNP) and N-terminal pro-BNP
(NT-proBNP), can be useful biomarkers in the diagnosis of
HF [11]. Values which excludes heart failure in patients not
treated for heart failure are BNPo100 pg/ml and NT-proBN-
Po400 pg/ml. In patients treated for heart failure normal
values of BNP or NT-proBNP does not exclude heart failure.Systemic
ia Raise of weight
eart sound Peripheral oedema
ilatation Raised jugular venous pressure
icle hypertrophy Hepatomegaly
eriferial pulsation Hepatojugular reflux
Cyanosis
Ascites
ns Weakness
ia Tiredness
Sweating
Nycturia
Oliguria
Insomnia
Nausea
Vomiting
Obstipation
 noitanimaxe lacinilC
ECG, chest X-ray 
Echocardiography
Natriuretic peptides
BNP < 100 pg/ml 
NT-proBNP
< 400 pg/ml 
BNP 100–400 pg/ml 
NT-proBNP
400–2,000 pg/ml 
BNP > 400 pg/ml 
NT-proBNP
> 2,000 pg/ml 
Chronic HF 
unlikely
Uncertain
diagnosis
Chronic HF 
likely
Fig. 1 – Diagnosis of chronic heart failure using natriuretic peptides.
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in diagnosis of heart failure according to ESC guidelines.
In acute heart failure (including decompensation of chronic
heart failure) patently pathological values are BNP4400 pg/ml,
NT-proBNP42000 pg/ml [1].
BNP and NT-proBNP measurements were introduced as
tools for diagnosis, prognostic markers and tools for monitor-
ing drug therapy [12].
In clinical praxis the evaluation of natriuretic peptide is
most important for exclusion of heart failure in untreated
patients. (Normal values of BNP does not exclude structural
impairment like constrictive pericarditis or mitral stenosis.) The
evaluation of natriuretic peptides should lead to minor use of
echocardiography and other specialized diagnostic methods.
4.3. Electrocardiogram
If the ECG is completely normal, heart failure, especially with
systolic dysfunction, is unlikely (10%). Thereby the predictive
value to eliminate systolic dysfunction of left ventricle is over
90%. Among patients with HF supraventricular arrhythmias,
ventricular arrhythmias, different level conduction blocks,
atrial overload, hypertrophy and overload of ventricles, ST-T
segment changes can be found on ECG. All these ECG changes
are highly nonspecific. Besides these nonspecific changes
signs of causing disease (Q waves after MI etc.) can be found.
4.4. Chest X-ray
Cardiomegaly can be often found in chronic HF, but not
always, not even if systolic heart failure is present. Cardiac
size enlargement can be found and also the contour of heart
shadow can be changed. Cardiothoracic ratio (ratio of cardiac
shadow width to the width of thorax) is used to assess cardiac
size. Values over 0.5 are considered to be pathological.
Patients without pulmonary hypertension tend to have non-
enlarged pulmonary blood vessels without pulmonary conges-
tion (stage 0) [13]. Pulmonary hypertension first manifests itself
as enlarged hilar vessels, lately the distribution of pulmonary
blood vessels filling is changed (stage 1). Shadows of pulmonary
vessels filling in healthy person can be seen on chest X-ray made
in upright position just in low and middle lung fields. With
increasing pulmonary vessel pressure pulmonary vessels filling
can be found even on upper lung fields. Next level of pulmonary
congestion is interstitial pulmonary oedema (stage 2). Alveolar
pulmonary oedema is a sign of acute left heart failure or severeworsening of chronic HF (stage 3). Oedema can be unilateral or
bilateral.
4.5. Echocardiography
Echocardiography is one of the basic imaging techniques in
confirming the diagnosis of chronic heart failure, since it
allows evaluating and quantifying the dysfunction of left and
right ventricle.
The basic parameter for diagnosis of left ventricle (LV)
systolic failure is ejection fraction (EF). For left ventricular
dysfunction is considered to decrease in EF below 50%, a
significant systolic dysfunction is defined by the values of
LVEF below 40%. An important additional data, in particular
to assess the prognosis of heart failure, are also end-diastolic
and end-systolic dimension and volume (EDV, ESV) of LV. All
of these parameters, as well as the assessment of LV wall
movement, can be obtained from one-dimensional (M-mode)
and two-dimensional (2-D) transthoracic echocardiography,
recently the three-dimensional (3-D) echocardiography has
begun in use.
Pulsed Doppler echocardiography of transmittal filling of LV
can obtain the following basic clinically useful parameters.
They are early diastolic mitral inflow velocity (E), late diastolic
mitral inflow velocity (A) and deceleration time of early
diastolic mitral flow (DT) [14]. With parallel recording of
transaortic and early diastolic mitral flow velocity an
isovolumic relaxation time (IVRT) can be measured. The
greatest expansion in the assessment of diastolic LV function
and LV filling pressure estimation was achieved by tissue
Doppler echocardiography, using the measurement of mitral
annulus movement velocity in early diastole (Ea) and during
atrial contraction (Aa) [15]. These parameters are less
influenced by preload and afterload in comparison with
parameters measuring the filling velocities of LV. Measuring
analogous parameters of tricuspidal annulus can noninva-
sively evaluate and quantify the function of right ventricle. It
is very useful to combine the measurement of Ea and Aa
movement of mitral annulus by tissue Doppler echocardio-
graphy with the evaluation of E and A by pulsed Doppler
echocardiography of transmittal LV filling. Combination of E
and Ea measurements can nearly accurately noninvasively
estimate the increased LV filling pressure. Nagueh et al. [14]
showed good correlation between the ratio E/Ea and pul-
monary capillary wedge pressure (r ¼ 0.87). The ratio E/Eao8
is a sign of normal mean diastolic left ventricle filling
Table 6 – Normal range of most commonly used echocardiographic parameters of diastolic function of left ventricle at
different age categories.
Parameter Age 16–20 years Age 21–40 years Age 41–60 years Age over 60 years
E/A 1.8870.45 1.5370.40 1.2870.25 0.9670.18
DT (ms) 142719 166714 181719 200729
Duration of A wave (Ad, ms) 113717 127713 133713 138719
Duration of wave Ard (ms) 66739 96733 112715 113730
Ea sep (cm/s) 14.972.4 15.572.7 12.272.3 10.472.1
Ea lat (cm/s) 20.673.8 19.872.9 16.172.3 12.973.5
Values are given as mean7standard deviation. E—early diastolic mitral flow velocity, A—late diastolic mitral flow velocity, DT—deceleration
time of early diastolic mitral flow, Ard—duration of reverse flow in pulmonary veins during atrial contraction, Ea sep and lat—septal (sep) and
lateral (lat) early diastolic mitral annulus movement velocity in early diastole.
 LV diastolic dysfunction de-
termination
Tissue Doppler 
echocardiography
Natriuretic peptides 
concentration
E/Ea > 15 E/Ea 8–15 BNP > 200 pg/ml 
or
NT-proBNP
> 220 pg/ml 
BNP > 200 pg/ml 
or
NT-proBNP ¨ 
> 220 pg/ml 
Atrial fibrillation or other echo 
parameters:
LAVi > 40 ml/m2
or
LVMi > 122 g/m2 (female)
LVMi > 149 g/m2 (male) 
or
E/A < 0,5 a DT > 280 ms 
or
Ard-Ad > 30 ms 
E/Ea > 8 
Fig. 2 – Noninvasive diagnostic algorithm for LV diastolic dysfunction assessment [15]. Note: normal ranges for natriuretic
peptides in this modification are different then ranges for diagnosis of heart failure in ESC guidelines.
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lic pressure [16].
Table 6 shows normal normal range of most commonly
used echocardiographic parameters of diastolic function of
left ventricle at different age categories [17] (Fig. 2).4.6. Selective coronary angiography, left and right cardiac
catheterization
In patients with chronic heart failure, coronary angiography is
used mainly for explaining the cause of heart failure and to
assess prognosis. Dyspnoea of cardiac aetiology or left
ventricle dysfunction are clear indications for coronary
angiography. Also severe valvular heart disease is an indica-
tion for coronary angiography. CT angiography shows promis-
ing for the future, especially in patients where we expect a
negative finding on the coronary vessels. If noninvasive
methods fail for evaluating the cause of left ventricular
dysfunction, it is possible to perform left-heart catheterizationwith assessment of systolic and diastolic parameters of left
ventricular function or right-heart catheterization with
measurement of pulmonary capillary wedge pressure, which
indirectly inform us about the left ventricle inflow pressure
[18]. During the cardiac catheterization (and also indepen-
dently of it) endomyocardial biopsy can be performed when
heart failure due to infiltrative or storage disease is suspected.4.7. Magnetic resonance imaging
Magnetic resonance imaging represents a great prospect for
quantitative assessment of myocardial viability and function
of left and right ventricle. Increased accumulation of gadoli-
nium after intravenous administration in nonviable part of
myocardium (positive late enhancement) indicates a pre-
sence of irreversible myocardial damage (connective tissue
transformation, scar). Nuclear magnetic resonance imaging
can highly accurately determine standard (e.g. EF) as well as
new parameters of myocardial function (e.g. analysis of
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 1 1 3 – e 1 3 4e120myocardial deformation–strain). Magnetic resonance is also
indicated when myocardial lesion due to infiltrative or storage
diseases is suspected.
Currently also CT scans begin to be tested for myocardial
function and viability evaluation.
4.8. The role of individual methods in diagnosis of chronic HF
Table 7 and Fig. 3 show the diagnostic procedure.5. Treatment strategy of chronic heart failure
5.1. Prevention
Primary prevention of heart failure represents prevention and
strict treatment of all diseases that may lead to ventricular
dysfunction. These include treatment of hypertension,
arrhythmias, acute forms of ischaemic heart disease with the
aim of the earliest recanalization of occluded artery, optimal
timing of surgical treatment of valvular heart diseases andTable 7 – Summary of diagnostic assessment of CHF.
Necessary for diagnosi
of CHF
Compatible symptoms þþþ
Compatible signs
Response to therapy þþ (If symptoms or dysfunc
absent)
ECG
Objective evidence of dysfunction (ECHO
and other)
þþþ
Chest X-ray
BNP, NT-proBNP
Suspicion of chronic heart failure 
(signs and symptoms)
Perform: ECG + Chest X-ray 
Note: without echo or (NT-pro)BNP is 
not sufficient for ruling out 
pathological findings  
Perform echocardiography, BNP or 
NT-proBNP
(possible isotopic examination or 
MRI) 
pathological findings  
Establish aetiology and severity of 
systolic dysfunction
A
c
in
Treatment selection  
Fig. 3 – Algorithm forprevention of specific myocardial diseases, in which the causality
is known and removable (alcohol, cardiotoxic cytostatics, some
endocrinopathies).
Secondary prevention of heart failure is meant to prevent
the progression of preexisting ventricular dysfunction to
manifestation of heart failure and progression of existing
heart failure. Tools for primary and secondary prevention are
often identical. Progression of heart failure can also be
prevented or at least significantly slowed down by medica-
tions such as ACE inhibitors, ARBs, betablockers or aldoster-
one receptors blockers. An essential part of secondary
prevention is elimination of all worsening conditions and
factors that include myocardial ischaemia, hypertension,
arrhythmia, inflammatory diseases, anaemia, hyperthyroid-
ism, metabolic disorders etc.
Class of recommendation I, level of evidence A.
5.2. Objectives and treatment options
The purpose of heart failure treatment is to improve the quality
of life, i.e. reduce or completely eliminate symptoms, improves Supports the diagnosis
of CHF
Opposes the diagnosis
of CHF
þþþ (If absent)
þþþ þ (If absent)
tion þþþ þþ (If absent)
þ þþ (If normal)
þþþ (If absent)
þþþ þ (If normal)
þ þþþ (If normal)
physiological 
findings = heart 
failure unlikely 
physiological 
findings = heart 
failure unlikely
otgnidroccanoitanimaxelanoitidd
linical state (angiography, stress test-
g, etc.) 
diagnosis of CHF.
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tancy [19]. For each patient, the order and importance of these
aims can be different. For mildly symptomatic patients it is prior
to reduce mortality and slowing the disease progression. For
severely symptomatic patients it is more important to release
from symptoms and improve the quality of life. Current
treatment options, always individualised for each patient, can
bring remarkable results (Table 8). Causal therapy of heart failure,
such as surgical reconstruction or replacement of damaged heart
valves, effective treatment of hypertension, revascularization
procedures etc., may be realized only in some patients.
The choice and combination of optimal treatment strategy
depends on the underlying disease, severity of CHF, co-
morbidities, patient age and number of other factors. Non-
pharmacological options such as regimen and diet are an
essential part of comprehensive treatment.
5.3. Triggering factors, specific causes and co-morbidities
If we find factors causing CHF, which are treatable, it is always
necessary to intervene. Their removal sometimes leads to
re-compensation. They can be divided into1.T
S





P










S





Volume overload (increased preload): excessive physical or
emotional burden, fever, infections (bronchopulmonary,
urinary), mitral or aortal valve insufficiency, anaemia,
acute abdomen, thyrotoxicosis, drugs that cause sodium
and water retention (NSAIDs, corticosteroids), excessive
salting, hypervolemia, etc.able 8 – Treatment options for heart failure.
elf-care and diet recommendations:
Weight reduction in patients with overweight and obese
limit salt intake o4–5 g a day
Abstinence (restriction) of alcohol
Smoking cessation
Adequate physical exercise (except for acute heart failure)
harmacological treatment:
Angiotensin-converting enzyme inhibitors (ACEIs)
Angiotensin receptor blockers (ARBs)
Beta-blockers (BB)
Aldosterone antagonists
Diuretics
Digoxin
Ivabradine
Vasodilators anticoagulants, antiplatelet agents
Amiodarone
Positive ionotropic agents (PDE inhibitors, catecholamines,
levosimendane)
urgery and devices:
Surgical (CABG) or catheter (PCI) revascularization
Cardiac resynchronization therapy
Implantable cardioverter-defibrillator
Left ventricular assist devices
Elimination methods: ultrafiltration, haemodialysis
Heart transplantation2. Pressure overload (increased afterload): hypertension,
aortic stenosis, excessive physical burden predominantly
isometric, etc.3. Myocardial damage: missed medication, negative ionotro-
pic agents (antiarrhythmics, alcohol), NSAIDs, new onset
of ischaemia or myocardial infarction, electrolyte, acid-
obasic or respiratory disturbances, inflammatory myocar-
dial disease, urinary retention, etc.
5.4. Self-care management
5.4.1. Everyday activities
Patient education plays a fundamental role for appropriate
self-care behaviour management: patient should have an
adequate knowledge of his disease and treatment to improve
the most the adherence to all procedures. The education
and psychological support should be provided to him at
every opportunity by healthcare professionals and relatives.
The patient should weigh himself on a regular basis,
preferably in the morning after emptying. A weight gain of
1 kg from day to day already suggests fluid retention. In case
of sudden weight gain of 42 kg in 3 days, well cooperating
patient may increase his diuretic dose or contact his doctor.
The patient should have an adequate knowledge of his
medical treatment including possible side effects. He should
also be aware about medication which would be inappropri-
ate. These are mainly NSAIDs (notice over-the-counter drugs as Ibalgin, Brufen,
Voltaren, Diclofenac, Veral) including coxibs are contra-
indicated for long term use in severe heart failure; some calcium channel blockers (verapamil, diltiazem,
short-acting dihydropyridines); tricyclic antidepressants;
 corticosteroids;
Class of recommendation I, level of evidence C.
Patients in NYHA functional classes I–III are free to drive
motor vehicles for private purposes, professional drivers
must be in NYHA functional class I or II, with EF440% and
without ventricular tachycardia (repeated mandatory testing
once a year). In NYHA functional class IV is not allowed to
drive motor vehicles.
5.4.2. Diet
It is based on a rational balanced diet with enough nutrients
and maintaining an optimal weight. Weight reduction in
overweight and obese is necessary.
Intake of salt depends on the severity of disease. Even
patients with mild heart failure should have the salt intake
less than 5 g per day before diuretics are ordered. Salt shaker
removal out of table and avoidance of food that contains large
amounts of salt (smoked meat, white bread, canned food,
mineral water) could be helpful.
Alcohol is absolutely contraindicated in alcohol-induced
cardiomyopathy. Moderate alcohol consumption is allowed
for other patients with maximal day limit of 40 g for men and
30 g for women (that is equivalent to 1 beer or 1–2 dl of wine
per day).
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Fluids should not be significantly restricted with an optimal
intake of 1.5–2 l per day. Fluid restriction is considered in
patients with severe symptoms accompanied by hyponatre-
mia, but always with strict monitoring of fluid balance and
serum electrolytes.
Cardiac cachexia: a clinical or subclinical malnutrition is
presented in approximately 50% of patients with advanced
heart failure. It is an important predictor of worse prognosis.
Cardiac cachexia is likely when: documented unintentional weight loss of Z5 kg or Z7.5%
from the previous stable weight without the presence of
oedema; BMIo22 kg/m2.
The patient with cardiac cachexia should attempt toTable 9 – Recommended daily dosage of ACE inhibitors in
chronic heart failure.
Generic name Starting dose
(mg)
Target dose
(mg)
Captopril 36.25 350
Enalapril 22.5 220
Lisinopril 12.5 120
Perindopril–Erbumine 12–2.5 18–10
Perindopril–Arginine 12.5 110
Ramipril 12.5 110
Trandolapril 10.5 14
Note 1: captopril and enalapril are the oldest ACE inhibitors
historically with RCTs made in 80s and 90s of 20th century and
today they have been already replaced by modern ACE inhibitors
with once a day dosage.increase the muscle mass by performing the exercise training
regularly. The weight gain by fluid retention is undesirable.
Class of recommendation I, level of evidence C.
5.4.3. Exercise
The level of physical activity depends on the patient’s current
condition. It varies from resting, preferably in a chair for
patients in NYHA functional class IV, to regular daily activity
excluding the heavy physical strain in patients in NYHA
functional classes I–II. Disability pension should be consid-
ered for the patients in NYHA III–IV functional classes in
relation to individual situation. Regular exercise is recom-
mended for all patients with mild or moderate functional
limitations. Exercise training is recommended to stable
patients in NYHA I–III functional classes without malignant
ventricular arrhythmias or other contraindications. 20–30 min
of dynamic exercise up to individual submaximal level (e.g.
cycling or fast walking) completed with daily morning exercise
3–5 times a week is crucial.
Class of recommendation I, level of evidence C.
5.4.4. Travelling
Travelling to very hot and humid destinations is not
recommended as well as high altitudes. Long flights in which
there is a risk of dehydration, peripheral edemas and deep
vein thrombosis, are not recommended. On the contrary, air
travel is preferable to long journeys than travelling by bus.
Class of recommendation I, level of evidence C.
5.4.5. Sexual activity
Sexual activity cannot be dictated. It is important to reassure
anxious patients and also their sometimes even more
anxious partners. Phosphodiesterase 5 (PDE5) inhibitors (e.g.
sidenafil, tadalafil, vardenafil, etc.) are not currently recom-
mended for patients with an advanced heart failure (NYHA
III–IV) and they are strictly contraindicated for those using
nitrates.
5.4.6. Influenza vaccination
Annual influenza vaccination is extremely underestimated in
general population. Influenza is very serious disease that
causes large number of deaths, especially for patients with
chronic illness. It is mainly recommended for people over 65years and people with chronic diseases. Data from rando-
mized clinical trials show that annual influenza vaccination
leads to reduction in morbidity and mortality in patients with
cardiovascular disease. Using live attenuated vaccines with
intranasal administration is not recommended yet [20].
Class of recommendation I, level of evidence C.
5.5. Pharmacological therapy
5.5.1. Angiotensin-converting enzyme inhibitors (ACEIs)
ACE inhibitors are drugs of first choice in chronic heart failure
even when asymptomatic left ventricular dysfunction [1,2]. A
meta-analysis of clinical trials showed that the average
decline in mortality is 23% and in total mortality and
morbidity (measured by number of hospitalisation) even
35%. Differences in demanded effects and side effects are
irrelevant [21,22]. Due to individual hypotensive response and
possible worsening of renal functions (especially in elderly
patients with pre-existing chronic renal insufficiency) the
initial dose, so-called testing dose, should be small, with up-
titration until the maximum tolerated. Overview of ACE
inhibitors and their recommended dosage in chronic heart
failure are listed in Table 9 (we present only ACE inhibitors
where the effect was proven in mortality trials) [23–27].
Class of recommendation I, level of evidence A.
First finished randomized double-blind trial PEP CHF
showed safety, improvement of quality of life and reduction
of the number of admissions to hospital [28]. The trial I
Preserve did not prove the benefit of irbesartan [29]. On the
base of these trials we consider ACE inhibitors as a possible
treatment for diastolic heart failure (especially when left
ventricular hypertrophy presented).
Class of recommendation IIa, level of evidence B.
ACE inhibitors are well tolerated. Adverse effects are rare,
except hypotension and troublesome cough. Those are renal
function impairment, often in elderly patients, skin rush,
angioneurotic oedema, sensory disturbance, more rarely
leucopenia and glomerulopathy with proteinuria. Combina-
tion potassium-sparing diuretics therapy (except spironolac-
tone) may be dangerous for a risk of hyperkalemia. Severe
renal insufficiency is a contraindication but the exact plas-
matic creatinine level and glomerular filtration rate is not
Table 11 – Recommended daily doses of ARB in chronic
heart failure.
Generic name Starting dose (mg) Target dose (mg)
Candesartan 1 4 1 16–32
Losartan 1 25 1 100
Valsartan 2 40 2 160
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ACEI while monitoring renal functions (the level of serum
creatinine 4180 mmol/l is an exclusion criterion in most
clinical trials). Other contraindications are hyponatremia and
hypovolemia caused by massive diuretic treatment, absolute
contraindication then bilateral renal artery stenosis, history
of angioneurotic oedema and pregnancy (for teratogenic
effect). Dry troublesome cough appears in 5–10% of patients
and it usually leads to discontinuation of ACE inhibitor. The
change of product is not usually helpful and the cough
disappears rarely after dose reduction. If an ACE inhibitor
causes a cough, switch to ARB is indicated.
Table 10 shows the strategy for initiation of ACE inhibitors
therapy.5.5.2. Angiotensin receptor blockers (ARB)
First clinical trials with ARB in patients with chronic heart
failure have shown improvement of hemodynamical para-
meters and improvement in exercise tolerance. Other trials
have shown equal effect of ARB on mortality and morbidity as
ACE inhibitors. Adding ARB to ACEI did not lead to a further
decrease in mortality. In the VALIANT trial in patients after
myocardial infarction, the addition of ARB led to an increase
in side effects, but in the CHARM trial it decreased the
number of hospitalisations [30].
The current findings about angiotensin receptor blockers in
heart failure and after myocardial infarction can be summarised–T
th
1
2
3
4
5
6
7Indications of ARB are the same as indications for ACEI.
ARB are recommended in patients intolerant of ACEI.
Recommendation I, level of evidence A.– We do not have proof that ARB are better than ACEI,
therefore they are the drug of choice in heart failure only
in case of intolerance of ACEI.able 10 – Strategy for initiation of ACE inhibitors
erapy.
. Avoid high doses of diuretics before starting the treatment
for a risk of hypovolemia, diuretics should be discontinued
for 24 h
. The first dose of ACE inhibitor to be taken at bedtime to
minimise the possible hypotensive effect. When the therapy
is started in the morning, the patient should be monitored
for several hours (3–4 h), including blood pressure checks
. Always begin with small, so-called test dose and slowly up-
titrate to recommended maintenance doses
. Renal functions and serum electrolytes should be checked
every 3–5 days during the dose up-titration. After the
maintenance dose is reached and the patient is stable, the
check should be once every 3 months, later once every 6
months. When the renal function is worsening, the
treatment usually has to be discontinued
. Never simultaneously start the treatment with potassium-
sparing diuretics! Reduce the dose or discontinued
established potassium-sparing diuretics therapy and
continue only in case of persistent hypokalemia
. Do not administer NSAIDs, they reduce the effectiveness of
ACE inhibitors
. Check blood pressure every 1–2 weeks after each dose
increase– The benefits of combined therapy with ACEI and ARB on
mortality have not been proven. This combination is
appropriate in patients with inadequately controlled
hypertension or marked proteinuria. Combination therapy
decreases the amount of hospitalisations for heart failure
and it requires careful follow-up controls.
Recommendation IIa, level of evidence B.Recommended starting and target doses of ARB (only those
ARB that have mortality trials in heart failure are shown in
Table 11).
Similarly as in ACE inhibitors, we start treatment with a
dose equal to approximately 1/4 of the target dose and we
uptitrate the doses in 7–14-days’ intervals.
Recommendation I, level of evidence A–C.
The HEAAL trial investigated the efficacy of low and high
doses of losartan: 50 mg vs. 100 mg. It proved a decrease in
death or hospitalisation for heart failure in the group of
patients with the higher dose. Patients in this group observed
improvement of symptoms and a lower risk of side effects
was found [31].
Recommendation I, level of evidence B.
Note:
Direct inhibitors of renin, mainly aliskiren, are currently in
phase III. trials. In the clinical trial ALOFT (Aliskiren observa-
tion of heart failure treatment) in patients with stable heart
failure, aliskiren significantly decreased the plasma renin
activity and the levels of brain natriuretic peptide. Mortality
trials in patients with chronic heart failure with the accro-
nyms ATMOSPHERE and ASTRONAUT are ongoing.
5.5.3. Betablockers (BB)
Betablockers should be used in all patients with heart failure
(NYHA II–IV) when the patient is stabilized, in both ischaemic
and nonischaemic aetiology, and decreased LVEF, unless they
are contraindicated. Their positive effect on mortality, func-
tional improvement and delay of progression of heart failure
was observed without difference in sex, age, functional class
or level of LVEF in clinical trials.
Recommendation I, level of evidence A.
BB are always indicated after myocardial infarction (unless
contraindicated), even in asymptomatic patients with LV
dysfunction (NYHA I), in combination with ACEI/ARB, as
demonstrated in the CAPRICORN study [32].
Recommendation I, level of evidence B.
Due to different clinical effects of betablockers, only those
betablockers that have clear positive mortality data from
double blind multicentric studies: bisoprolol, carvedilol,
metoprolol succinate (ZOK) and nebivolol are recommended.
Recommendation I, level of evidence A.
Table 13 – Recommended daily doses of betablockers in
chronic heart failure.
Generic name Starting dose (mg) Target dose (mg)
Bisoprolol 1 1.25 1 10
Carvedilol 2 3.125 2 25–50
Metoprolol ZOC 1 25 1 200
Nebivolol 1 1.25 1 10
Table 14 – Recommended daily doses of diuretics in
chronic heart failure.
Generic name Initial dose
(mg)
Max. daily dose
(mg)
Furosemide 20–40 250–500
Hydrochlorothiazide 12.5–25 50
Chlorthalidone 12.5–25 50
Indapamide 1.25–2.5 5
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effects of ACEI (CARMEN). The two groups of drugs do not
compete with each other, instead combined therapy is
favourable. The positive effect of betablockers can be
explained mainly by decrease of sympatoadrenal activation,
decrease in heart rate, an increase in the length of diastole
and by their antiarythmic effect [33].
As demonstrated by the CIBIS III trial, heart failure
treatment can be started either with a betablocker with the
addition of an ACE inhibitor, or the other way around. In mild
forms of heart failure with signs of sympaticotonia, it is better
to start with a betablocker and after their titration to add ACEI
or ARB. On the other hand, in more severe cases of HF it is
recommended to stabilise the patient with an ACEI or with
diuretics, and start the titration of betablockers afterward.
Importantly, combined therapy should be used, unless
contraindicated [34].
Recommendations for starting treatment and steps to be
followed in case of adverse effects during treatment are
shown in Table 12. The recommended doses are shown in
Table 13 (only those betablockers that have mortality trials in
heart failure are included) [1].
Absolute contraindications of betablockers: asthma, severe
forms of COPD, symptomatic bradycardia and hypotension
should be respected. We always consider the risks and
benefits in relative contraindications: diabetes mellitus with
possible hypoglycaemia, less severe forms of COPD (perform
spirometry before starting BB, than test BB), PAD.Table 12 – Recommendations for starting treatmentswith
BB and recommendations in case of worsening during
treatment.
Practical recommendations for treatment with betablockers in
CHF:
1. The patient must be clinically stable on established conventional
therapy of heart failure (ACE inhibitors, diuretics, ev. digoxin).
Patients in functional class NYHA IV must be hemodynamically
stable (on oral diuretic therapy)
2. Start the treatment with a low dose, uptitrate slowly
3. Uptitrate dose every 2–4 weeks, if well tolerated. Try to achieve
target dose. During every visit monitor BP and HR, clinical
condition, ev. changes in weight (increased weight can signal fluid
retention)
4. Inform the patient of the possibility of temporary worsening of
symptoms when betablockers are started
5. We must acknowledge that patient improvement can be seen
after 3–6 months of uninterrupted therapy
Steps to be followed in case of adverse effects:
1. In hypotension correct dose of ACEI or diuretics and slow down
titration of BB
2. In temporary worsening HF when BB are started, increase dose
of ACEI or diuretics and slow down titration until negative effects
subside
3. Add digoxin, if patient not already on it
4. Do not abruptly discontinue BB, but leave a lower dose, which is
better than no dose
5. Increase doses of BB slower to achieve maximal or maximal
tolerated doses. Adverse effects that can limit dose include
bradycardia, fatigue, weakness and gastrointestinal symptoms5.5.4. Diuretics
Diuretics combined with ACEI and betablockers are considered as
core therapy in patients with pulmonary or systemic congestion.
We do not give diuretics to asymptomatic patients, in absence of
dyspnoea or oedema. In mild forms of heart failure, thiazide
diuretics are the first line therapy, in more severe forms of heart
failure loop diuretics (in our country most frequently furosemide)
are chosen. In case of insufficient response, loop and thiazide
diuretics can be combined [35].
Recommendation I, level of evidence C.
Diuretics are recommended in patients with HF and clinical
signs or symptoms of congestion.
Diuretics have not been investigated in a double-blind
mortality trial. The combination with drugs affecting the
renin angiotensin system and betablockers is common [36].
Recommendation I, level of evidence C.
In severe forms of heart failure or in case of poor response
to loop diuretics, a combination of loop and thiazide diuretics
is favourable [37].
Dosing of diuretics is shown in Table 14.
The indication for diuretic use is to relieve signs of congestion
and fluid retention. Dehydration should be avoided.
We can change the doses of diuretics in patients with good
compliance according to their current condition, for example
according to their daily weight.
We start therapy with low doses together with ACEI/ARB. In
case glomerular filtration (GF) is below 0.5 ml/s, we do not add
thiazide diuretics (they are ineffective), but we give loop
diuretics instead (furosemide).
It is important to actively observe possible side effects:
hypovolaemia, worsening of renal parameters, hypokalaemia,
hypomagnesaemia, hyponatraemia, hyperuricaemia, impaired
blood glucose, acid-base balance disorders, with amiloride
hyperkalaemia.
In insufficient response, we increase the dose to twice daily,
combine loop and thiazide diuretics. Aware patients to
exclude use of other nephrotoxic agents e.g. NSAIDs.
Table 16 – Recommended daily doses of BRA in chronic
heart failure.
Generic
name
Initial dose
(mg)
Maximal daily dose
(mg)
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lixivaptan), are being tested in clinical trials. They seem to be
promising in patients with hyponatraemia and worsened
heart failure, even though the EVEREST study has not yet
proven their benefit when compared to loop diuretics [38].Spironolactone 12.5–25 25–50
Eplerenone 25 25–505.5.5. Aldosterone receptor blockers
Hyperaldosteronism, which is a part of neuroendocrine
activation and is associated with heart failure, causes the
depletion of potassium and magnesium, fibrosis in the
myocardium and blocks reverse reuptake of noradrenaline.
It therefore worsens myocardial function and increases the
predisposition to arythmias. It worsens endothelial function
in blood vessels, it worsens compliance of arteries by
increasing the amount of collagen and destroys the micro-
circulation (vasculitis like changes). The increased level of
aldosterone can be suppressed by the administration of ACEI/
ARB only temporarily (aldosterone escape).
The RALES (Randomized Aldactone Evaluation Study),
proved a positive effect of aldosterone antagonists on the
prognosis and symptoms in patients with heart failure. A 30%
reduction in mortality was observed.
Based on the results from the above study, therapy with low
doses of spironolactone is indicated in patients with LVEFo35%,
and those in functional class NYHA III–IV or those who recently
had an episode of circulatory decompensation and are treated
with a loop diuretic. The recent EMPHASIS_HF trial with the
new aldosterone antagonist eplerenone showed its positive
effect even in less severe forms of heart failure [39].
The recommended doses of both drugs are 25 mg daily. In case
of hyperkalaemia, the dose should be decreased by half,
alternatively other concomitant therapy should be adjusted.
The discontinuation of aldosterone blockers should be avoided if
possible. In case of refractory heart failure without hyperkalae-
mia with the regular dose, the dose can be increased to 50 mg per
day. Careful monitoration of potassium levels is needed as
hyperkalaemia can occur (Tables 15 and 16) [40].
Recommendation I, level of evidence A.Table 15 – Strategies for administration of aldosterone
receptor blockers.
Patient NYHA II–IV or post MI with LV dysfunction
Check plasma concentration of potassium (o5 mmol/l) and
creatinin (o250 mmol/l)
Start with low dose of spironolakton 12.5–25 mg; eplerenon 25 mg
Check plasma concentration of potassium and creatinin after one
week
The higher plasma potassium concentration above 5.0 mmol/l BRA
reduce the dose to 50% for potassium above 5.5 mmol/l
discontinue BRA
If symptoms of CHF persist after a month and lasts normokalemie
increase BRA dose to 50 mg daily
BRA contraindications: Anuria, acute renal insufficiency, markedly
decreased renal function, hyperkalemia, hyponatremia, porphyria,
hypersensitivity to ingredients of BRA, pregnancy and lactation5.5.6. Digoxin
From digitalis glycosides, in our country we exclusively use
digoxin. There has been a single mortality/morbidity trial with
digoxin, and this was done before betablockers were routinely
used in chronic heart failure [41]. According to the DIG trial,
digoxin does not affect all cause mortality. It decreases the
number of hospitalisations for heart failure and it decreases the
mortality for heart failure. Digoxin therefore improves sympto-
matic condition of patients with heart failure, but it does not
affect their prognosis. The reduction of symptoms seems to be
higher, in patients with more severe LV dysfunction and in more
symptomatic patients [42].
The results of the DIG trial are supported by a metanalysis
of smaller studies [43].
A clear indication for chronic digoxin therapy is chronic
symptomatic heart failure with systolic dysfunction of left
ventricle with atrial fibrillation with rapid ventricular re-
sponse. In asymptomatic systolic LV dysfunction and atrial
fibrillation, digoxin can be used for rate control, but digoxin
only influences heart rate at rest, and not during exercise.
Therefore betablockers are the drugs of choice, if needed they
can be combined with digoxin.
Recommendation I, level of evidence C.
The administration of digoxin in heart failure and sinus
rhythm remains contradictory. Digoxin still has a wide
popularity for some of its benefits. It can be administered
once per day, it had good short and long term tolerance,
tachyfylaxation does not occur, and it is inexpensive. The
current consensus is that digoxin can be beneficial in sinus
rhythm in patients with manifested heart failure and more
severe left ventricular systolic dysfunction. It should be tried
in these patients, and if it leads to clinical improvement, it
should be administered regularly. If it does not lead to clinical
improvement, it should be discontinued.
Recommendation IIa, level of evidence B.
In heart failure with preserved ejection fraction (HFPEF),
digoxin is indicated only for control of heart rate with
simultaneous atrial fibrillation with rapid ventricular re-
sponse. There are no benefits in sinus rhythm.
Recommendation IIb, level of evidence B.
Digoxin is not suitable in heart failure during acute
myocardial infarction and sinus rhythm, as its effect is
unpredictable and it can cause serious arythmias. It is
contraindicated in significant bradycardia, second- or third-
degree heart block, sick sinus syndrome (in the absence of a
permanent pacemaker), carotic sinus syndrome, WPW syn-
drome, obstructive hypertrophic cardiomyopathy, hypokalae-
mia, hypercalcaemia and in case of previous intolerance of
digoxin. Digitalization is ineffective in chronic cor pulmonale,
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tamponade and constrictive pericarditis.
Recommendation I, level of evidence B.
Before starting treatment with digoxin, renal functions and
kalemia levels must be determined. The usual daily dose is
0.125–0.250, in older patients 0.0625–0.125. For chronic treat-
ment, a booster dose is not needed. Digoxin is eliminated
almost completely by the kidneys, and its clearance is similar
to that of creatinine. It is therefore important to reduce daily
dose in patients with renal failure, according to given
nomograms and equations. Certain drugs can interfere with
the pharmacokinetics of digoxin and they can increase
plasma digoxin levels twofold (chinidine, propafenone, amio-
darone, verapamil and others). Therefore the adjustment of
the daily dose is needed. The therapeutic blood levels of
digoxin are 0.6–1.2 ng/ml [44].
5.5.7. Antiaggregation, anticoagulation
Clinical data from observational trials show that patients with
chronic heart failure have a higher risk of thromboembolism
(deep vein thrombosis, pulmonary embolism, peripheral arterial
embolizations and ischaemic brain infarctions) [45].
Thromboembolic events are the third most common cause
of death in patients with chronic heart failure [46,47]. The
cause is not only the frequently present atrial fibrillation but
also the activation of coagulation due to platelet dysfunction,
endothelial dysfunction and inflammatory activation not only
in patients with atrial fibrillation, but also in patients with
sinus rhythm. These disorders are proportional to the level of
left ventricular dysfunction and severity of symptoms [48].
The effectivity of antiaggregation therapy in patients with
heart failure and sinus rhythm is debated, as acetylsalycic acid
(ASA) can decrease the effect of ACE inhibitors by decreasing
Prostaglandin synthesis in the kidney and this unfavour-
able interaction can lead to an increase in worsening of heart
failure [49,50].
We recommend administration of ASA to all patients with
proven ischaemic aetiology of heart failure, with doses
between 75 mg and 160 mg/day. Caution is needed in patients
with refractory heart failure and frequent decompensations
where we consider risk versus benefit.
Recommendation IIa, level of evidence B.
In patients with atrial fibrillation, anticoagulation therapy is
indicated, as it strongly decreases the number of thromboem-
bolic events when compared to placebo and ASA.
Anticoagulation therapy is indicated in patients CHF and– History of systemic or pulmonary embolism.– With atrial fibrillation—dabigatran is indicated in patients
with atrial fibrillation and heart failure.– Intracardial thrombus.– After an extensive Q myocardial infarction of anterior wall
with aneurysm.– Significant left ventricular dilatation of nonischaemic
aetiology.– With LVEF below 20%.
Target INR for effective anticoagulation is 2.0–3.5. Antic-
oagulation therapy with INRo2.0 is ineffective.Heparin or preferably low molecular weight heparins are
the drug of choice during acute decompensations, pulmonary
embolism, recent intracardial thrombus, venous thrombosis,
preoperative and postoperative treatment.
Recommendation I, level of evidence A.5.5.8. Hypolipidemic therapy
There is no reason to stop statin therapy in patients that are
already treated with a statin for example for a previous
myocardial infarction in secondary prevention. On the other
hand, there is no reason to start patients on statin therapy
due to chronic heart failure.5.5.9. If channel blockers
In patients with heart failure and sinus rhythm, heart rate at
rest above 70/min is considered as a negative prognostic
factor. The trials BEAUTIFUL and mainly SHIFT, proved
positive effect of ivabradin, a drug that inhibits If channels
in the sinus node, and therefore decreases the heart rate,
without having other negative effects on the myocardium
[51,52].
Ivabradin is indicated in patients with compensated heart
failure and sinus rhythm, who have heart rate at rest above
70/min, even if on maximal tolerated dose of betablockers. It
must be differentiated if present tachycardia is a compensa-
tory mechanism in patients with low cardiac output. The
recommended starting dose is 2 mg2.5 mg, the maximal
daily dose is 2 mg7.5 mg. According to EMA, the recom-
mended heart rate to start ivabradin is 75/min. (EMA citation).
Recommendation I, level of evidence B.5.6. Recommendations for pharmacological therapy of
systolic cardiac dysfunction
The principles of pharmacological therapy of chronic systolic
heart failure are summarised in Table 17.5.7. Elimination methods
Haemodialysis is used in severe kidney dysfunction and
there, where the elimination of excessive fluids is required.
The basic principles are diffusion and filtration. Diffusion is
the exchange of substances according to the concentration
gradient on the semipermeable membrane (SM). During
ultrafiltration, water and substances dissolved in it cross the
SM according to the pressure gradient [53,54].
For patients that mainly need removal of fluids, without the
need for haemodialysis, continual elimination methods are
available. In this case we mainly use ultrafiltration.
The indication is acute pulmonary oedema and congestive
heart failure accompanied by renal insufficiency due to
hypoperfusion, without the ability to eliminate the retained
fluids (subacute and chronic pulmonary oedema, anasarca
resistant to pharmacological treatment). Chronic nephropa-
thy (ischaemic kidney disease, diabetic nephropathy, chronic
tubulointersticial nephritis), drug damage (antibiotics,
NSAIDs) may participate.
Table 17 – Principles of therapy of chronic heart failure.
Level of
importance
Drug of choice
1. Asymptomatic
dysfunction of
left ventricle
(EFo40%)
ACEI (ARB in case of intolerance)þBB
2. Symptomatic
diastolic
dysfunction
(NYHA II–III,
EFZ40%)
ACEIþBBþdiuretics
3. Systolic
dysfunction LV
NYHA II–III,
stable state
ACEIþBBþaldosterone blockersþdiuretics
Digoxin (in atrial fibrillation)
Ivabradin (in SR a HR470/min
In maximal tolerated or targeted dose of BB)
4. NYHA III–IV,
progressing state
ACEIþBBþdiureticsþdigoxinþaldosterone
blockers, nitrates?
5. Decompensation
of heart failure
with signs of
hypervolaemia
ACEIþBBþdiuretics i.v.þdigoxinþaldosterone
blockersþdopamine?
6. Decompensation
of heart failure
with signs of low
cardiac output
ACEIþBBþdiuretics i.v.þdigoxinþaldosterone
blockersþinotropes
Note 1: In atrial fibrillation, an effort to restore sinus rhythm (if not
contraindicated), always anticoagulation, if not contraindicated.
Note 2: Strict control of diabetes mellitus.
Note 3: Optimal levels of lipids and optimal blood pressure values
are not known, in ischaemic aetiology, values used in secondary
prevention of CAD are recommended.
Note 4: In decompensation of heart failure it is a must to modify
doses of ACEI, BB and diuretics. After compensation, an effort to
return to previous doses.
Note 5: In heart failure of ischaemic origin ASA.
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therapy in patients with heart failure
Current recommendations for cardiac resynchronization
therapy (CRT) in patients with heart failure are based on
Guidelines for cardiac pacing and resynchronization therapy
with pacemaker/defibrillator function of Czech society of
Cardiology issued in 2009 and newly published Guidelines on
device therapy in heart failure of European society of
Cardiology from 2010 [55,56].
In contrast to previous guidelines, this update is focused on
the clinical state of the patients with heart failure, analyses
the results of newly published important clinical trials in this
area and introduces the indications of CRT in patients in
NYHA II functional class.
Meta-analysis of clinical trials with less symptomatic
patients (NYHA I–II) and patients with advanced heart failure
(NYHA III–IV) clearly shows that CRT is an effective therapy in
adequately selected patients with any NYHA class [57].
It should be emphasised that there is still no clear predictor
of long term efficacy of CRT as well as the definition of so-
called non-responders to this treatment despite the use of
sophisticated echocardiographic and other imaging and
electrophysiological methods [58].The indication for cardiac resynchronization therapy re-
mains highly individual, with regard to clinical state, co-
morbidities, pharmacological treatment and the overall
perspective of the patient.
Optimally indicated CRT should be based on consensus of
the arrhythmologist and heart failure and echocardiography
specialists.
The clinical effects of long-term CRT, where CRT-P or CRT-D
(biventricular pacemakers or implantable cardioverter-defi-
brillators) were implanted, have been evaluated in a large
number of randomized multi-centre trials and registries
[59–62].
Meta-analyses were also published [63], suggesting that the
most efficacious option to reduce mortality in patients with
heart failure and low left ventricular ejection would be a CRT-D.
The most common inclusion criteria were: NYHA func-
tional class III or IV despite optimal pharmacological treat-
ment, left ventricle ejection fraction LVEFr35%, sinus rhythm
(SR), left ventricular (LV) dilatation but with varying defini-
tions, and QRS durationZ120/Z130 ms [64].
The results support the use of resynchronization therapy to
improve morbidity (but not mortality) in ambulatory class IV
patients with the exception of patients eligible for cardiac
transplantation, where the aim is to reduce the mortality before
the surgery.
Key points: Left ventricle dilatation is no longer required in a
recommendation. NYHA class IV patients should be ambulatory.
 Reasonable expectation of survival with good functional
status for more than 1 year for CRT-D. Evidence is strongest for patients with typical left bundle
branch block (LBBB). Similar level of evidence for CRT-P and CRT-D in primary
prevention.
Recommendations in patients with heart failure in NYHA
III–IV functional class.
Patients in NYHA III–IV classes, with LVEFr35%, QRSZ120
m, sinus rhythm, optimal pharmacotherapy (NYHA class IV
patients should be ambulatory). CRT-P or CRT-D are recom-
mended to reduce mortality and morbidity.
Class of recommendation I, level of evidence A.
Four trials—MIRACLE ICD II [65], MADIT-CRT [66], REVERSE
[67] and RAFT [68, 69] assessed the role of CRT in patients
presenting with mild or no manifestations of heart failure,
low LVEF and wide QRS complex.
Currently there is no convincing evidence that CRT should be
indicated in patients with no or transient, mild symptoms
(NYHA I), and the recommendation is restricted to patients in
NYHA II.
Key points: Three recent, randomized, prospective, multicenter trials
(MADIT-CRT, REVERSE a RAFT) in mild HF demonstrated
reduced morbidity. Improvement primarily seen in patients with QRSZ150 ms
and/or typical LBBB.
Table 18 – Recommendations in patients with heart
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failure and a concomitant class I pacemaker indication.In MADIT-CRT, women with LBBB demonstrated a parti-
cularly favourable response.
Recommendations Patient population Class
CRT-P or CRT-D:
recommended to reduce
morbidity
NYHA III–IV,
LVEFr35%,
QRSZ120 ms
I BIn MADIT-CRT the extent of reverse remodelling was
concordant with and predictive of improvement in clinical
outcome.
Recommendations in patients with heart failure in NYHA II
functional class.
Patients in NYHA functional class II, with LVEFr35%,
QRSZ150 ms, sinus rhythm, optimal pharmacotherapy. CRT-
D is recommended to reduce morbidity and prevents the
progression of heart failure.
Recommendations are restricted to patients with HF in
NYHA II, QRSZ150 ms, in whom very good response to
treatment is expected. Patients with a secondary prevention
indication for an ICD should receive CRT-D.
Class of recommendation I, level of evidence A.
Approximately one-fifth of patients receiving CRTs in
Europe have permanent atrial fibrillation. The prevalence of
AF in patients with HF is linked to the severity of the disease:
5% in NYHA I as compared with 25–50% in NYHA III/IV
patients. Some patients with permanent AF may resume SR
during long-term treatment or following successful left atrial
ablation.
It should be emphasised that patients with symptomatic
HF, AF, and an LVEF of r35% may satisfy the criteria for ICD
implantation. The presence of QRS prolongation would favour
implantation of a CRT-D in these patients.
In that the evidence is limited in AF and most of the
patients included in trials had a very wide QRS width, we
restrict recommendation for CRT-P/CRT-D to QRSZ130 ms.
Key points: Approximately one-fifth of CRT implantation in Europe are
in patients with permanent AF. NYHA classes III–IV symptoms and LVEF of r35% are well
established indications for ICD. AV nodal ablation may be required to assure adequate
pacing. Evidence is strongest for patients with an LBBB pattern.
 Insufficient evidence for mortality recommendation.
Recommendations in patients with HF and permanent
atrial fibrillation.
Patients in NYHA classes III–IV, LVEFr35%, QRSZ130 ms
and pacemaker dependency induced by AV nodal ablation,
CRT-P/CRT-D should be considered to reduce morbidity [70].
Class of recommendation II, level of evidence B.
Patients in NYHA class III–IV, LVEFr35%, QRSZ130 ms.
CRT-P/CRT-D should be considered to reduce morbidity.
Class of recommendation II, level of evidence C.
Although prospective randomized controlled studies speci-
fically addressing the issue of CRT in patients with a narrow
QRS complex are currently lacking, there are several retro-
spective observational series or small prospective trials
demonstrating a clinical benefit of upgrading to biventricular
pacing with long-standing right ventricular pacing, severe
ventricular dysfunction, NYHA functional class III symptoms,
regardless of QRS duration [71,72]. This may indirectlyindicate that preservation and/or restoration of an intrinsic,
near-normal activation sequence by biventricular pacing
should be pursued regardless of rhythm.
Key points: In patients with a conventional indication for pacing,
NYHA III/IV symptoms, an LVEF ofr35%, and a QRS width
of Z120 ms, a CRT-P/CRT-D is indicated. RV pacing will induce dyssynchrony.
 Chronic RV pacing in patients with LV dysfunction should
be avoided. CRT may permit adequate up-titration of beta-blocker
treatment.
Recommendations in patients with heart failure and a
concomitant class I pacemaker indication are summed up in
Table 18.5.9. Artificial heart and ventricular assist devices
Mechanical assist devices are pumps that are partially able to
take over the heart’s function and restore sufficient cardiac
output (Table 19).
Currently there is a whole range of systems for short- and
long-term ventricular assistance [73]. In patients with ad-
vanced chronic heart failure, nonpulsatile implantable left
ventricular assist device (LVAD) is most frequently implanted
[74]. LVAD is used as a bridge to heart transplantation (CTX) in
patients in end-stage heart failure and in patients with
progressive clinical deterioration and expectation of short
survival (Table 20). Further indications are severe pulmonary
hypertension [75] and cardiac cachexia as a result of low
cardiac output in candidate for cardiac transplantation.
Contraindications for ventricular assist devices are shown
in Table 21.
Health care of patients with implanted LVAD should be
complex, consisting of close cooperation of specialized nurse,
physician and a technician. Infection or bleeding during the
anticoagulant therapy is the most common complication.
Patients with LVAD do not necessarily have to be hospitalised,
although they are placed on top positions on the heart
transplant waiting list. Short-term assist devices are used in
emergency situations—after a cardiac surgery, in CTX as a
right ventricle assist device in patients with pulmonary
hypertension. Correctly indicated mechanical assist device
improves the prognosis for patients and enables a successful
CTX.
Class of recommendation I, level of evidence A.
Table 19 – Summary of recommendations for cardiac resynchronization therapy.
Baseline
rhythm
NYHA
class
Indication criteria Class of
recommendation
Level of
evidence
Aim of therapy
Recommended
devices
SR III–IV LVEFo0.35, QRS4120 ms, optimal medical
therapy of heart failure. Patients in NYHA
IV should be ambulatory and expectation
of survival should be 46 months
I A Reduction of
morbidity and
mortality
Use of CRT-P or
CRT-D
SR II (I) LVEFo0.35, QRS4150 ms, optimal medical
therapy of heart failure. Insufficient
evidence for NYHA I class
I A Reduction of
morbidity,
mortality and
progression of
heart failure
Preferred use of
CRT-D
AF III LVEFo0.35, QRS4130 ms, PM dependency
following AV/AF ablation with slow
ventricular response and frequent
stimulation
IIa B/C Reduction of
morbidity
Use of CRT-P or
CRT-D
Concomitant
class I
pacemaker
indication and
heart failure
III, IV LVEFo0.35, QRS4120 ms, optimal medical
therapy of heart failure
I B Reduction of
morbidity
III, IV EF LKo0.35, QRSo120 ms, optimal medical
therapy of heart failure
IIa C Use of CRT-P or
CRT-D
II LVEFo0.35, QRSo120 ms, optimal medical
therapy of heart failure
IIb C
Table 20 – Indications for LVAD as a bridge to trans-
plantation.
Patient eligible for, or considered for heart transplant programme
NYHA class III–IV
Inotropic support dependency
Heart failure refractory to maximal medical therapy
LVEFo25%
PWP420 mmHg
CVPo18 mmHg
Cardiac index CIo2.2 l/min/m2
BSA41.2 m2
Table 21 – Contraindications for LVAD.
Active, uncontrollable infection
Irreversible cognitive, neurologic or severe psychiatric disorder
Insufficiently treated thyroid disorder, obstructive
cardiomyopathy, amyloidosis or restrictive cardiomyopathy as an
underlying mechanism of heart failure
Intolerance of anticoagulant therapy
Malignancy
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There are no data from multicentre trials assessing the
benefit of percutaneous coronary revascularization in pa-
tients with chronic heart failure. However, smaller studies
suggest functional and prognostic benefit of myocardial
revascularization (for both coronary bypass grafting andpercutaneous coronary intervention) in case of dysfunctional
but viable (hibernating) myocardium supplied by significantly
stenotic coronary artery. If angina pectoris or exertional
ischaemia is present, indication criteria for myocardial
revascularization in chronic ischaemic heart disease should
apply and these patients should be considered at higher risk.
Class of recommendation I, level of evidence C.5.11. Surgery
Surgery is indicated when surgically correctable conditions of
heart failure are present. Patients with acceptable risk profile
for surgery should be considered.5.11.1. Myocardial revascularization
Coronary angiography is indicated in patients with ischaemic
left ventricular dysfunction and myocardial revascularization
should be considered. Proof of viable myocardium supplied by
stenotic or occluded coronary arteries is an important factor
in favour of revascularization. The most frequent methods of
myocardial viability assessment are dobutamine stress echo-
cardiogram, myocardial perfusion scintigraphy and magnetic
resonance imaging. In correctly indicated patients, sympto-
matic improvement and increase of LVEF may be expected.
Randomized trial STICH proved decreased hospitalisation and
death rate during 5 years following intervention [76].
Class of recommendation I, level of evidence B.
Mitral valve repair should be performed in patients with
severe mitral regurgitation. In patients with left bundle
branch block, implantation of stimulating electrode on lateral
wall of left ventricle for future resynchronization therapy is
Table 22 – Indications for heart transplantation.
NYHA III or IV with optimal pharmacotherapy
 No conventional cardiac surgery treatment possible
 VO2max less than 10 ml/kg/min
 PVRo3.5 wood units
Ischaemic heart disease with intractable angina
 Not suitable for revascularization
 Maximal conventional therapy not effective
 Previous revascularization was not successful
Refractory malignant arrhythmias
 No alternative treatment
Hypertrophic cardiomyopathy
 Symptoms of NYHA class IV despite maximal therapy
Congenital heart disease
 Absence of fixed pulmonary hypertension
Absence of contraindications
Table 23 – Contraindications for heart transplantation.
Absolute
active malignancy or other serious illness with poor prognosis
chronic infection with no possibility of healing
fixed pulmonary vascular resistance (pulmonary vascular
resistance 43.5 Wood units, PVR ¼ (MAPPCWP)/CO,
TPG415 mmHg, systolic pressure in pulmonary artery460 mmHg)
psychiatric disorder or ongoing history of substance abuse
BMI greater than 40
Relative
age greater than 65 years
diabetes mellitus with complications
renal and liver function disturbances
generalised atherosclerosis
psychosocial instability
BMI greater than 30
Temporary
active infection
unhealed pulmonary infarction
active gastroduodenal ulcer disease
MAP—mean pulmonary arterial pressure; PCWP—pulmonary ca-
pillary wedge pressure; PVR—pulmonary vascular resistance;
TPG—transpulmonary gradient.
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and/or atrial reduction should be considered.
Class of recommendation IIa, level of evidence C.
5.11.2. Aneurysmectomy
In symptomatic patients with LV aneurysm, aneurysmectomy
is indicated, most frequently in anterior wall and interven-
tricular septum area.
Class of recommendation IIb, level of evidence B.
In patients with vast anterior wall akinesis indicated for
surgery, LV endoventriculoplasty may be considered. In
randomized trials there is no evidence of prognosis improve-
ment after this procedure.
Class of recommendation IIb, level of evidence B.
5.11.3. Mitral valve surgery
In patients with ischaemic left ventricular dysfunction and
severe mitral valve regurgitation, mitral valve surgery should
be considered when coronary revascularization is an option.
Class of recommendation I, level of evidence C.
Surgical correction in patients with non-ischaemic left
ventricular dysfunction may improve symptoms.
Class of recommendation IIa, level of evidence C.
5.11.4. Aortic valve replacement
It is recommended in patients with severe aortic valve
stenosis, as well as in patients with both aortic valve stenosis
and LV dysfunction. Severe aortic regurgitation may be
considered for replacement before important LV dilatation
and remodelling occurs.
Class of recommendation I, level of evidence C.
5.12. Heart transplantation
Heart transplantation is an accepted treatment for patients in
end-stage heart failure with no alternative form of medical
therapy [77]. Patients in NYHA class IV (or advanced III) with
severe LV dysfunction (EFo20%) and poor prognosis should be
considered. End-stage heart failure is mostly due to ischaemic
heart disease or dilated cardiomyopathy. Dyspnoea and
fatigue are most limiting factors. Patients with severe angina
pectoris or severe rhythm disturbances with no alternative
treatment options may exceptionally be considered for CTX.
In patients in NYHA III class, expectation of survival and
prognosis is decisive. The assessment should be comprehensive,
including spiroergometry. Indications for CTX are summarised in
Table 22. Peak VO2r10 ml/kg/min is a clear indication for CTX,
with peak VO2 above 14 ml/kg/min, the CTX is usually not
necessary. When the values are between 10–14 ml/kg/min, the
presence of hyperventilation helps assess stratification (VE/VCO2
slope435 represents worse outcome).
Indications for cardiac transplantation are summed up in
Table 23.
Contraindications for cardiac transplantation are shown in
Table 23.
Patients after heart transplantation require continuous
long-term care provided by specialized cardiology centre in
cooperation with a cardiologist. The greatest complications
during first months following surgery are graft rejection and
infections, hypertension, obesity, hyperlipidemia, osteoporo-sis, renal failure, cardiac allograft vasculopathy and increased
incidence of malignancies. Heart transplantation significantly
improves patients’ quality of life and prognosis. Perioperative
mortality is approximately 10%, 1-year survival 80% and 5-
year survival around 70%. The heart transplant programme is
limited, depending on number of donors, therefore this
treatment can be offered only to a fraction of patients
suffering from heart failure.
Class of recommendation I, level of evidence C.
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failure
Chronic heart failure leads, sooner or later, to death. It may be
sudden, based on malignant arrhythmia or pulmonary
embolism, or terminal failure of the heart as a pump. In the
latter case the close cooperation of health care professionals,
the patient and close relatives is necessary to comfort the
dying patient. Patients in terminal phase must be free of
agonising pain and dyspnoea and their fear of dying should be
moderated. In case the patient has an ICD, its inactivation
may be offered. The use of opiates, inotropic agents and high-
dose diuretics to alleviate the symptoms should not be feared
[78–81].6. Heart failure management programs
Any physician should be able to diagnose acute heart failure,
ensure basic treatment and refer the patient to the closest
intensive care unit at the internal medicine department or
coronary care unit at cardiac centre. Most ambulances are
equipped with 12-lead ECG, often connected to the closest
coronary care unit or invasive angiography department and in
case of acute coronary syndrome with heart failure, take the
patient directly to one of these specialized centres.
Should the first contact physician discern signs of heart
failure in his patient, clinical examination, ECG, chest X-ray
and basic laboratory tests should be performed and the
patient referred to a cardiologist? The cardiologist should
ensure the echocardiogram, BNP or NT-pro-BNP testing and
consider further specialized exams.
A patient with chronic heart failure should be taken care of
by a cardiologist cooperating with the general practitioner.
The heart failure issue has become important to such an
extent, that it is advisable to establish specialized outpatient
centres and departments within inpatient cardiology depart-
ments. In patients with severe left ventricular dysfunction or
advanced/end-stage heart failure, it is necessary to refer them
to a heart transplant centre.
Patients with left bundle branch block in NYHA III or IV
class, or patients in NYHA I–III class with malignant
arrhythmias should be referred to a centre specialized in
resynchronization therapy and implantation of ICDs. In
patients with advanced heart failure possibly eligible for
heart transplantation, it is recommended to contact the heart
transplant centre, where the resynchronization or/and ICD
implantation could be performed as a bridge to transplanta-
tion.
Patient with stable heart failure should be taken care of by
general practitioner, including drugs prescription. The gen-
eral practitioner manages the timing of further check-ups,
which should be indicated with any clinical deterioration.
With every check-up the history should be updated, clinical
examination with blood pressure and pulse measurement
performed. An ECG, chest X-ray and basic laboratory tests
should be carried out at least once a year. At least once in 6
months a check-up by a cardiologist should be arranged. The
cardiologist indicates specialized examinations such as
echocardiography and other.The health condition of patients with heart failure may
often require hospitalisation. These patients should be
hospitalised at cardiology units within internal medicine
departments at the catchment area hospital. According to the
results of the EURO HEART SURVEY, 25% of patients hospita-
lised at internal medicine departments in Czech Republic
have chronic heart failure and the in-hospital mortality is 7%.
Patients being prepared for prospective heart transplanta-
tion should be examined on an inpatient basis in heart
transplant centres. In Czech Republic these are currently
Cardiology Department, Institute of clinical and experimental
medicine (IKEM) in Prague (Klinika kardiologie, IKEM, Praha)
and 1st Department of Internal Medicine, Cardioangiology, St.
Anne’s University Hospital Brno (I. internı´-kardioangiologick a
klinika FN u sv. Anny v Brneˇ). The surgery itself is performed
at Cardiovascular surgery clinic IKEM Prague (Klinika
kardiovaskul arnı´ chirurgie Praha) and Cardiovascular Surgery
and Transplant Centre in Brno (Centrum kardiovaskul arnı´ a
transplantacˇnı´ chirurgie Brno). The resynchronization ther-
apy and implantation of ICDs is performed by most of larger
hospitals (University Hospital, Hospital Na Homolce, IKEM
Prague etc.).
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